Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
Hands-on clinical workshop in Bengaluru brings together neurologists, ENT specialists and physicians
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Subscribe To Our Newsletter & Stay Updated
